ClinicalTrials.gg
RecruitingNCT05420584NECIUpdated May 11, 2023

Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer

A Phase 2 interventional study of Arterial chemoembolization and Tislelizumab Injection in Rectal Neoplasms, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing tislelizumab in Rectal Neoplasms — 8 open to participants now, 8 under way, 1 of them phase 3. tislelizumab · Rectal Neoplasms.

Planned enrollment
5th of 12
83 · median 55
Started
2022
the only one that year
Phase 2
10 of 12
6 open now
Registered
4th of 12
by date
Lead sponsor
1 of 12
The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Among the 12 studies testing tislelizumab in Rectal Neoplasms, this one is the 5th largest by planned enrollment, is the only one that started in 2022, is one of 10 in phase 2, and was the 4th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

8 of the 12 studies testing tislelizumab in Rectal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tislelizumab in Rectal Neoplasms, or all of them as a file.
02

Study summary

Rectal cancer is one of the common malignant tumors of the digestive tract. Some patients with rectal cancer are already advanced tumors when they are first diagnosed. At this time, the tumor has local infiltration, the probability of recurrence and metastasis after surgical resection is high, and even radical tumor resection cannot be performed. Neoadjuvant chemotherapy and radiotherapy have become one of the important treatment methods for these patients to increase the rate of radical tumor resection. However, a series of side effects of neoadjuvant radiotherapy can even continue after the end of radiotherapy, and even increase the incidence of postoperative complications. Superselective arterial interventional chemotherapy has been widely used in preoperative neoadjuvant chemotherapy for various tumors, and its efficacy in rectal cancer has also been confirmed. In addition, as a hot spot in tumor treatment, tumor immunotherapy has shown exciting effects in the NICHE study of neoadjuvant immunotherapy before colon cancer surgery. Moreover, Oxaliplatin is a classic chemotherapeutic drug that induces Immunogenic cell death effects, which induce antitumor immunity.

Therefore, in order to optimize the preoperative neoadjuvant therapy plan, the investigators propose a treatment method of superselective arterial chemoembolization combined with immunotherapy and systemic chemotherapy, in order to obtain better preoperative conversion therapy effect and reduce the adverse reactions of neoadjuvant therapy.

03

Conditions studied

  • Rectal Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed rectal adenocarcinoma (immunohistochemistry, polymerase chain reaction(PCR) or next-generation sequencing(NGS) sequencing methods are acceptable).
  2. Magnetic resonance imaging (MRI) measurement of tumor inferior margin ≤12cm from the anus.
  3. MRI staging is cT3-4 N0 or cT1-4 N+, no multiple primary cancers or distant .
  4. ≥ 1 year.
  5. No anti-tumor therapy, no to interventional embolization, immunotherapy and chemotherapy.
  6. Patients who understand the study protocol and are willing to participate in this study provide written .

Exclusion criteria

Exclusion Criteria:

  1. Refuse to participate in this study.
  2. Multifocal colorectal cancer.
  3. Past history of , excluding basal cell carcinoma/papillary thyroid carcinoma/various types of carcinoma in situ.
  4. Inability to receive chemotherapy, such as but not limited to bone marrow suppression, etc.
  5. Major organ diseases (such as but not limited to , coronary heart disease and renal insufficiency, etc.) during acute exacerbation and or severe acute infectious diseases (such as but not limited to hepatitis, pneumonia and myocarditis, etc.), (ASA) score > 3.
  6. Mental disability or illiteracy or language and communication barriers cannot understand the research protocol.
  7. There are to arterial puncture, such as but not limited to severe arteriosclerosis or even atresia, coagulation dysfunction, long-term use of anticoagulants and cannot be stopped, etc.
  8. Obstruction or high risk of obstruction by rectal tumor and/or bleeding and/or perforation.
  9. Peripheral sensory nerve disorder, unable to receive oxaliplatin-based chemotherapy.
  10. Lateral pelvic lymph node (mainly supplied by the internal iliac artery).
  11. Pregnancy or breastfeeding.
  12. Contraindications for MRI。
  13. Consecutive use of for more than 3 days within 1 month before signing the consent form。
  14. MRI assessment was T4b or MRF positive。
  15. Other scenarios deemed inappropriate by the investigators for this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (estimated)

Study arms

  • Experimental
    experimental arm

    Procedure: Arterial chemoembolization · Drug: Tislelizumab Injection · Drug: XELOX · Diagnostic Test: Pelvic MRI · Procedure: Laparoscopic radical resection of rectal cancer

Interventions

  • ProcedureArterial chemoembolization

    The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.

  • DrugTislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.

  • DrugXELOX

    Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.

  • Diagnostic testPelvic MRI

    Pelvic MRI to evaluate efficacy

  • ProcedureLaparoscopic radical resection of rectal cancer

    Surgical treatment for patients who meet the surgical conditions

06

What researchers measure

Primary outcomes

  1. Imaging Tumor Regression Rate

    Tumor regression on imaging after neoadjuvant therapy

    Time frame: From date of the start of drugs treatment until the end of drugs treatment (nearly 3 weeks)

Secondary outcomes

  1. Pathologic Complete Response

    There is no histological evidence of malignancy in the primary tumor and metastatic regional lymph nodes, or there is only a carcinoma in situ component

    Time frame: From date of the start of drugs treatment until the operation is completed (nearly 4 weeks)

  2. Disease Free Survival

    Time from postoperative disease-free survival to disease recurrence or metastasis

    Time frame: 36 months

  3. Safety (The side effects)

    The side effects of this study

    Time frame: 36 months

  4. Pathological Tumor Regression Rate

    Tumor regression on pathology after neoadjuvant therapy

    Time frame: From date of the start of drugs treatment until the end of drugs treatment (nearly 3 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, Guthrie A, Bees N, Swift I, Pennert K, Brown G. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011 Oct 1;29(28):3753-60. doi: 10.1200/JCO.2011.34.9068. Epub 2011 Aug 29. PubMed 21876084 ↗
  • Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, Kuiper M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020 Apr;26(4):566-576. doi: 10.1038/s41591-020-0805-8. Epub 2020 Apr 6. PubMed 32251400 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2024, 24 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 24 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2022
First posted
Jun 15, 2022
StartActual
Nov 29, 2022
Primary completionEst.
Nov 30, 2024
CompletionEst.
Oct 31, 2025
Last update
May 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05420584
Responsible party
Sponsor
First posted
Jun 15, 2022
Start date
Nov 29, 2022
Primary completion
Nov 30, 2024 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
May 11, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Xelox

Start the discussion